Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial
Authors
Keywords
Type 2 diabetes, Sodium glucose cotransporter-2 inhibitor, Dapagliflozin, Heart failure, Impedance cardiography
Journal
Cardiovascular Diabetology
Volume 18, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-08-14
DOI
10.1186/s12933-019-0910-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Uric acid and the cardio‐renal effects of SGLT2 inhibitors
- (2019) Clifford J. Bailey DIABETES OBESITY & METABOLISM
- Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
- (2019) Eri T. Kato et al. CIRCULATION
- SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
- (2019) Chenguang Li et al. Cardiovascular Diabetology
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care
- (2019) Elisabetta Patorno et al. CIRCULATION
- Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes
- (2018) Daisuke Matsutani et al. Cardiovascular Diabetology
- The effect of dapagliflozin treatment on epicardial adipose tissue volume
- (2018) Takao Sato et al. Cardiovascular Diabetology
- The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
- (2018) Merlin C. Thomas et al. DIABETOLOGIA
- SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
- (2018) Subodh Verma et al. DIABETOLOGIA
- Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology
- (2018) Petar M. Seferović et al. EUROPEAN JOURNAL OF HEART FAILURE
- The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels
- (2018) Hongliang Li et al. LIFE SCIENCES
- Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes
- (2018) W. Timothy Garvey et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Trends and Disparities in Cardiovascular Mortality Among U.S. Adults With and Without Self-Reported Diabetes Mellitus, 1988–2015
- (2018) Yiling J. Cheng et al. DIABETES CARE
- Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2018) Aidin Rawshani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure
- (2018) Fumitaka Soga et al. Cardiovascular Diabetology
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts
- (2017) Tsung-Ming Lee et al. FREE RADICAL BIOLOGY AND MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
- (2017) Kåre I Birkeland et al. Lancet Diabetes & Endocrinology
- No Need to Sugarcoat the Message: Is Cardiovascular Risk Reduction From SGLT2 Inhibition Related to Natriuresis?
- (2016) Bruce A. Perkins et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design
- (2016) Jagdeep S. S. Singh et al. Cardiovascular Diabetology
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
- (2016) Ele Ferrannini et al. DIABETES CARE
- Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
- (2016) Antonius Baartscheer et al. DIABETOLOGIA
- In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry
- (2016) Giovanni Targher et al. EUROPEAN JOURNAL OF HEART FAILURE
- Impact of the 8-week Administration of Tofogliflozin for Glycemic Control and Body Composition in Japanese Patients with Type 2 Diabetes Mellitus
- (2016) Sachie Hirose et al. INTERNAL MEDICINE
- Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
- (2016) Sherif F. Nagueh et al. European Heart Journal-Cardiovascular Imaging
- Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
- (2015) R. Chilton et al. DIABETES OBESITY & METABOLISM
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
- (2015) Roberto M. Lang et al. European Heart Journal-Cardiovascular Imaging
- Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people
- (2015) Anoop Dinesh Shah et al. Lancet Diabetes & Endocrinology
- Electrical Bioimpedance Cardiography: An Old Technology With New Hopes for the Future
- (2014) Jean-Luc Fellahi et al. JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA
- Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats
- (2014) Atsuo Tahara et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- A New Equation to Estimate Glomerular Filtration Rate
- (2013) Andrew S. Levey et al. ANNALS OF INTERNAL MEDICINE
- Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
- (2013) H. J. Lambers Heerspink et al. DIABETES OBESITY & METABOLISM
- Impaired hemodynamic response to meal intake in insulin-resistant subjects: an impedance cardiography approach
- (2011) Saula Vigili de Kreutzenberg et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Noninvasive Monitoring of Transient Cardiac Changes with Impedance Cardiography
- (2009) Hongjun Zhang et al. Cardiovascular engineering (Dordrecht, Netherlands)
- Impedance cardiography versus invasive measurements of stroke volume index in patients with chronic heart failure
- (2009) Arne G. Kieback et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started